CN1043884C - 新的取代的氮杂环丁酮、其制法和药用 - Google Patents

新的取代的氮杂环丁酮、其制法和药用 Download PDF

Info

Publication number
CN1043884C
CN1043884C CN93119648A CN93119648A CN1043884C CN 1043884 C CN1043884 C CN 1043884C CN 93119648 A CN93119648 A CN 93119648A CN 93119648 A CN93119648 A CN 93119648A CN 1043884 C CN1043884 C CN 1043884C
Authority
CN
China
Prior art keywords
alkyl
amino
hydrogen
carbonyl
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN93119648A
Other languages
English (en)
Chinese (zh)
Other versions
CN1090272A (zh
Inventor
J·B·多赫蒂
C·P·多恩
P·L·杜雷特
P·E·芬克
M·麦克科斯
S·G·米尔斯
S·K·沙
S·P·沙胡
J·J·海尔
T·J·兰扎
W·K·哈格曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of CN1090272A publication Critical patent/CN1090272A/zh
Application granted granted Critical
Publication of CN1043884C publication Critical patent/CN1043884C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN93119648A 1992-10-27 1993-10-26 新的取代的氮杂环丁酮、其制法和药用 Expired - Fee Related CN1043884C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US96680092A 1992-10-27 1992-10-27
US966,800 1992-10-27
US99183892A 1992-12-17 1992-12-17
US991,838 1992-12-17

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN 98109505 Division CN1206004A (zh) 1992-10-27 1998-05-29 新的取代的氮杂环丁酮和应用

Publications (2)

Publication Number Publication Date
CN1090272A CN1090272A (zh) 1994-08-03
CN1043884C true CN1043884C (zh) 1999-06-30

Family

ID=27130493

Family Applications (1)

Application Number Title Priority Date Filing Date
CN93119648A Expired - Fee Related CN1043884C (zh) 1992-10-27 1993-10-26 新的取代的氮杂环丁酮、其制法和药用

Country Status (29)

Country Link
EP (1) EP0595557B1 (enExample)
JP (1) JPH082868B2 (enExample)
KR (1) KR950704250A (enExample)
CN (1) CN1043884C (enExample)
AT (1) ATE270273T1 (enExample)
AU (1) AU663806B2 (enExample)
CA (1) CA2108584C (enExample)
CY (1) CY2529B1 (enExample)
CZ (1) CZ106895A3 (enExample)
DE (1) DE69333563T2 (enExample)
DK (1) DK0595557T3 (enExample)
DZ (1) DZ1724A1 (enExample)
ES (1) ES2224095T3 (enExample)
FI (1) FI951992A7 (enExample)
HR (1) HRP931309A2 (enExample)
HU (2) HUT72084A (enExample)
IL (1) IL107321A (enExample)
LV (1) LV13338B (enExample)
MX (1) MX9306666A (enExample)
MY (1) MY128261A (enExample)
NO (1) NO305697B1 (enExample)
NZ (1) NZ257755A (enExample)
PL (1) PL308545A1 (enExample)
PT (1) PT595557E (enExample)
RU (1) RU2148056C1 (enExample)
SI (1) SI9300566A (enExample)
SK (1) SK53795A3 (enExample)
TW (1) TW275621B (enExample)
WO (1) WO1994010142A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5420010A (en) * 1993-07-30 1995-05-30 Merck & Co., Inc. Assay for evaluating inhibition of polymorphonuclear leukocyte elastase by N-substituted azetidinones
AU5014496A (en) * 1995-03-23 1996-10-08 Japan Tobacco Inc. Diphenylmethyl-azetidinone compounds and elastase inhibitor
US5523233A (en) * 1995-05-03 1996-06-04 Merck & Co., Inc. Enzymatic hydrolysis of 3,3-diethyl-4-[(4-carboxy)phenoxy]-2-azetidinone esters
CA2234640A1 (en) * 1995-10-31 1997-05-09 Merck & Co., Inc. Process for preparing substituted azetidinones
US5808056A (en) * 1995-10-31 1998-09-15 Merck & Co., Inc. Process for preparing substituted azetidinones
JP2000502079A (ja) * 1995-12-08 2000-02-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー アテローム性動脈硬化症の治療のための単環β―ラクタム誘導体
JP2000509049A (ja) * 1996-04-26 2000-07-18 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー アテローム性動脈硬化症の治療用アゼチジノン誘導体
CN1202081C (zh) * 1998-06-25 2005-05-18 布里斯托尔-迈尔斯斯奎布公司 脒基和胍基β－丙内酰胺类胰蛋白酶抑制剂
AU4654199A (en) * 1998-07-23 2000-02-14 Shionogi & Co., Ltd. Monocyclic beta-lactam compounds and chymase inhibitors containing the same
RU2191570C1 (ru) * 2001-04-25 2002-10-27 Закрытое акционерное общество "ВЕРОФАРМ" Твердая лекарственная форма антимикробного средства
RU2207115C1 (ru) * 2001-12-27 2003-06-27 Закрытое акционерное общество "Брынцалов-А" Противомикробное средство тариферид
RU2217196C2 (ru) * 2002-02-28 2003-11-27 Небольсин Владимир Евгеньевич Способ индукции дифференцировки клеток
FR2861991B1 (fr) * 2003-11-07 2008-01-18 Centre Nat Rech Scient Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose
FR2937972B1 (fr) * 2008-11-04 2013-03-29 Galderma Res & Dev Derives d'oxoazetidine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
KR101421785B1 (ko) * 2009-03-09 2014-07-22 다이호야쿠힌고교 가부시키가이샤 프로스타글란딘 ｄ 합성 효소를 저해하는 피페라진 화합물
FR2981933B1 (fr) * 2011-11-02 2013-11-15 Galderma Res & Dev Derives d'oxoazetidine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0337549A1 (en) * 1988-04-11 1989-10-18 Merck & Co. Inc. New substituted azetidinones as anti-inflammatory and antidegenerative agents
EP0481671A1 (en) * 1990-10-15 1992-04-22 Merck & Co. Inc. New substituted azetidinones as anti-inflammatory and antidegenerative agents
CN1068815A (zh) * 1991-06-25 1993-02-10 麦克公司 用做抗炎及抗变性剂的新的取代氮杂环丁酮

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0337549A1 (en) * 1988-04-11 1989-10-18 Merck & Co. Inc. New substituted azetidinones as anti-inflammatory and antidegenerative agents
EP0481671A1 (en) * 1990-10-15 1992-04-22 Merck & Co. Inc. New substituted azetidinones as anti-inflammatory and antidegenerative agents
CN1068815A (zh) * 1991-06-25 1993-02-10 麦克公司 用做抗炎及抗变性剂的新的取代氮杂环丁酮

Also Published As

Publication number Publication date
AU663806B2 (en) 1995-10-19
IL107321A (en) 1998-08-16
IL107321A0 (en) 1994-01-25
CN1090272A (zh) 1994-08-03
JPH082868B2 (ja) 1996-01-17
ES2224095T3 (es) 2005-03-01
CA2108584A1 (en) 1994-04-28
NZ257755A (en) 1998-03-25
SI9300566A (en) 1994-09-30
AU5028393A (en) 1994-05-12
RU2148056C1 (ru) 2000-04-27
LV13338B (en) 2006-01-20
EP0595557A1 (en) 1994-05-04
CY2529B1 (en) 2006-04-12
FI951992A0 (fi) 1995-04-26
SK53795A3 (en) 1995-09-13
WO1994010142A1 (en) 1994-05-11
NO951593D0 (no) 1995-04-26
DE69333563T2 (de) 2005-08-18
DK0595557T3 (da) 2004-10-25
NO305697B1 (no) 1999-07-12
ATE270273T1 (de) 2004-07-15
HRP931309A2 (en) 1997-02-28
EP0595557B1 (en) 2004-06-30
PT595557E (pt) 2004-10-29
MY128261A (en) 2007-01-31
RU95109936A (ru) 1997-01-10
TW275621B (enExample) 1996-05-11
CA2108584C (en) 1998-11-24
NO951593L (no) 1995-06-23
PL308545A1 (en) 1995-08-21
DZ1724A1 (fr) 2002-02-17
DE69333563D1 (de) 2004-08-05
JPH06263723A (ja) 1994-09-20
CZ106895A3 (en) 1996-03-13
MX9306666A (es) 1994-04-29
HU9501184D0 (en) 1995-06-28
FI951992A7 (fi) 1995-04-26
HUT72084A (en) 1996-03-28
KR950704250A (ko) 1995-11-17
HU211619A9 (en) 1995-12-28

Similar Documents

Publication Publication Date Title
CN1043884C (zh) 新的取代的氮杂环丁酮、其制法和药用
CN1257891C (zh) 含氮五员环化合物
CN1151136C (zh) 缩合哒嗪系化合物
CN1152866C (zh) 苯并咪唑,其制法及其作为药物组合物的用途
CN1286822C (zh) 嘧啶酮化合物
CN1216056C (zh) 氨基磺酸基异羟肟酸金属蛋白酶抑制剂
CN1118595A (zh) 氨茴酸衍生物
CN1037144A (zh) 用作为消炎剂和抗退化剂的新的取代的氮氧杂丁酮
CN1549817A (zh) 作为半胱氨酸蛋白酶抑制剂的吡咯并嘧啶化合物
CN1068815A (zh) 用做抗炎及抗变性剂的新的取代氮杂环丁酮
CN1845900A (zh) 作为嗜中性白细胞弹性蛋白酶抑制剂的喹啉衍生物及它们的用途
CN1678613A (zh) 杂芳基腈衍生物
CN1268133A (zh) 含有稠合环取代基的作为nos抑制剂的2－氨基吡啶
CN1845909A (zh) 作为嗜中性白细胞弹性蛋白酶抑制剂的喹喔啉衍生物及它们的用途
CN1560051A (zh) 取代吡唑化合物
CN1248259A (zh) 稠合的哒嗪衍生物、其生产方法和用途
CN1662498A (zh) 作为高血压蛋白原酶抑制剂的新型四氢吡啶衍生物
CN1926137A (zh) 作为Xa因子抑制剂的吡咯衍生物
CN1826111A (zh) 用于治疗变应性和过增生性疾病的咪唑衍生物
CN1950357A (zh) 用作tafia抑制剂的咪唑衍生物
CN1360577A (zh) 作为基质金属蛋白酶抑制剂的异羟肟酸衍生物
CN1523019A (zh) 三环三唑并苯并氮杂�衍生物、用于制备该衍生物的方法和抗变态反应剂
CN1173950C (zh) 2,3-二取代的吡啶衍生物、其制备方法、含有其的药物组合物和用于制备中的中间体
CN1960727A (zh) 用作组胺－3受体的配体的萘衍生物
CN1254334A (zh) 新颖的对苯二甲酰胺衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee